Cargando…
Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels
BACKGROUND: It is not well defined whether Guillain–Barré syndrome (GBS) patients with elevated serum creatine kinase (CK) levels have characteristic clinical features and are related to the subgroups of GBS. METHODS: We retrospectively studied 51 consecutive patients with GBS, who visited our hospi...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251688/ https://www.ncbi.nlm.nih.gov/pubmed/32460711 http://dx.doi.org/10.1186/s12883-020-01796-z |
_version_ | 1783539005745266688 |
---|---|
author | Hosokawa, Takafumi Nakajima, Hideto Sawai, Taiki Nakamura, Yoshitsugu Sano, Eri Tsukahara, Akihiro Unoda, Kiichi Ishida, Shimon Sakane, Sadaki Kimura, Fumiharu Arawaka, Shigeki |
author_facet | Hosokawa, Takafumi Nakajima, Hideto Sawai, Taiki Nakamura, Yoshitsugu Sano, Eri Tsukahara, Akihiro Unoda, Kiichi Ishida, Shimon Sakane, Sadaki Kimura, Fumiharu Arawaka, Shigeki |
author_sort | Hosokawa, Takafumi |
collection | PubMed |
description | BACKGROUND: It is not well defined whether Guillain–Barré syndrome (GBS) patients with elevated serum creatine kinase (CK) levels have characteristic clinical features and are related to the subgroups of GBS. METHODS: We retrospectively studied 51 consecutive patients with GBS, who visited our hospital, and compared clinical, laboratory and electrophysiological findings between patients with and without elevated CK levels. RESULTS: Of 51 patients, 14 patients (27%) showed an elevation of serum CK levels. When compared with patients with the normal CK levels, the ratios of male, antecedent infections, and anti-GM1 antibody positivity were significantly higher in patients with elevated CK levels. The ratios of hypoesthesia, cranial nerve involvement, and urinary retention were significantly less in patients with elevated CK levels. There were no significant differences in disability at peak between two groups. In the electrophysiological examination, sensory nerve abnormalities were not observed. Although some patients with elevated CK levels showed prolongation of distal motor latencies (DMLs) and increase of durations in the initial examination, development of the prolongation of DMLs and increase of durations was not observed in the follow-up examinations. The findings were consistent with acute motor axonal neuropathy (AMAN) with reversible conduction failure (RCF) but not acute inflammatory demyelinating polyneuropathy (AIDP). CONCLUSIONS: The results suggest that the GBS patients with elevated CK levels represent not a group of AIDP but a group of AMAN with axonal degeneration or RCF even though the initial electrophysiological examination shows AIDP pattern. |
format | Online Article Text |
id | pubmed-7251688 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-72516882020-06-04 Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels Hosokawa, Takafumi Nakajima, Hideto Sawai, Taiki Nakamura, Yoshitsugu Sano, Eri Tsukahara, Akihiro Unoda, Kiichi Ishida, Shimon Sakane, Sadaki Kimura, Fumiharu Arawaka, Shigeki BMC Neurol Research Article BACKGROUND: It is not well defined whether Guillain–Barré syndrome (GBS) patients with elevated serum creatine kinase (CK) levels have characteristic clinical features and are related to the subgroups of GBS. METHODS: We retrospectively studied 51 consecutive patients with GBS, who visited our hospital, and compared clinical, laboratory and electrophysiological findings between patients with and without elevated CK levels. RESULTS: Of 51 patients, 14 patients (27%) showed an elevation of serum CK levels. When compared with patients with the normal CK levels, the ratios of male, antecedent infections, and anti-GM1 antibody positivity were significantly higher in patients with elevated CK levels. The ratios of hypoesthesia, cranial nerve involvement, and urinary retention were significantly less in patients with elevated CK levels. There were no significant differences in disability at peak between two groups. In the electrophysiological examination, sensory nerve abnormalities were not observed. Although some patients with elevated CK levels showed prolongation of distal motor latencies (DMLs) and increase of durations in the initial examination, development of the prolongation of DMLs and increase of durations was not observed in the follow-up examinations. The findings were consistent with acute motor axonal neuropathy (AMAN) with reversible conduction failure (RCF) but not acute inflammatory demyelinating polyneuropathy (AIDP). CONCLUSIONS: The results suggest that the GBS patients with elevated CK levels represent not a group of AIDP but a group of AMAN with axonal degeneration or RCF even though the initial electrophysiological examination shows AIDP pattern. BioMed Central 2020-05-27 /pmc/articles/PMC7251688/ /pubmed/32460711 http://dx.doi.org/10.1186/s12883-020-01796-z Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research Article Hosokawa, Takafumi Nakajima, Hideto Sawai, Taiki Nakamura, Yoshitsugu Sano, Eri Tsukahara, Akihiro Unoda, Kiichi Ishida, Shimon Sakane, Sadaki Kimura, Fumiharu Arawaka, Shigeki Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels |
title | Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels |
title_full | Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels |
title_fullStr | Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels |
title_full_unstemmed | Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels |
title_short | Clinical features of Guillain–Barré syndrome patients with elevated serum creatine kinase levels |
title_sort | clinical features of guillain–barré syndrome patients with elevated serum creatine kinase levels |
topic | Research Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7251688/ https://www.ncbi.nlm.nih.gov/pubmed/32460711 http://dx.doi.org/10.1186/s12883-020-01796-z |
work_keys_str_mv | AT hosokawatakafumi clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT nakajimahideto clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT sawaitaiki clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT nakamurayoshitsugu clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT sanoeri clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT tsukaharaakihiro clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT unodakiichi clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT ishidashimon clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT sakanesadaki clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT kimurafumiharu clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels AT arawakashigeki clinicalfeaturesofguillainbarresyndromepatientswithelevatedserumcreatinekinaselevels |